31 results
8-K
EX-1.1
ATXS
Astria Therapeutics Inc
4 Mar 24
Entry into a Material Definitive Agreement
5:22pm
contemplated hereby, including without limitation (i) all expenses incident to the issuance and delivery of the Shares (including all printing and engraving … with, FINRA review, if any, and approval of the Agent’s participation in the offering and distribution of the Shares; (viii) the filing fees incident
8-K
EX-1.1
ATXS
Astria Therapeutics Inc
31 Jan 24
Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering
9:00am
obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i) all expenses incident to the issuance
8-K
EX-1.1
ATXS
Astria Therapeutics Inc
12 Oct 23
Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering
5:04pm
) all expenses incident to the issuance and delivery of the Offered Securities (including all printing and engraving costs), (ii) all fees and expenses
8-K
EX-3.1
8vs7butqr9l16i pqt
6 Jun 23
Departure of Directors or Certain Officers
8:00am
8-K
EX-1.1
iubnv b2w
15 Dec 22
Astria Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
5:18pm
8-K
EX-3.3
8ci88 5hxt4ypnj
8 Sep 21
Corporate Presentation September 2021 1 Confidential
5:31pm
8-K
EX-1.1
a9tbber16
30 Jun 21
Entry into a Material Definitive Agreement
4:25pm
424B3
3t4g5y1tb
16 Apr 21
Prospectus supplement
4:36pm
8-K
z0bzezvsj2580
29 Jan 21
Entry into a Material Definitive Agreement
8:05am
8-K
EX-10.2
aa02yl3 w7
29 Jan 21
Entry into a Material Definitive Agreement
8:05am
8-K
EX-1.1
74kpe t8112eiek2w
30 Jan 20
Catabasis Pharmaceuticals Announces Pricing of $23 Million Underwritten Public Offering
4:03pm